DMAC - DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia
2025-08-13 15:58:25 ET
The last time I wrote an article on DiaMedica Therapeutics Inc. ( DMAC ) it was with respect to a Seeking Alpha article entitled "DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point." In that article, I spoke in detail about it developing DM199 for the treatment of patients with Acute Ischemic Stroke [AIS] in the ongoing phase 2/3 ReMEDy2 trial. I also noted that the company would have an interim analysis done by now, but this wasn't the case. The company notes that it is still in the process of recruiting patients into this ReMEDy2 study and that an interim analysis on the first 200 patients is not likely to happen until Q2 of 2026....
DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia